Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex

Annals of Oncology

Volumn 11, Issue 8, 2000, Pages 977-983

  Sessa, C ^a,b   Capri, G ^b,c   Gianni, L ^b,c   Peccatori, F ^d   Grasselli, G ^b,c   Bauer, J ^e   Zucchetti, M ^b,f   Vigano L ^b   Gatti, A ^g   Minoia, C ^g   Liati, P ^b   Van den Bosch, S ^a   Bernareggi, A ^h   Camboni, G ^h   Marsoni, S ^b  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^b Southern Europe New Drug Organization SENDO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g IRCCS   (Italy)

^h NOVUSPHARMA   (Italy)

Author keywords

BBR3464; Pharmacokinetics; Phase I; Platinum analog

Indexed keywords

BBR 3464; PLATINUM DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYDRATION; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; URINARY EXCRETION; VOMITING;

EID: 0033802639     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008302309734     Document Type: Article

References (9)

1. Chemical studies and DNA binding of charged polynuclear platinum complexes
2. A novel charged trinuclear platinum complex effective against cisplatin-resistant xenografts
3. Accelerated titration designs for phase 1 clinical trials in oncology
4. Reporting results of cancer treatment
5. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
6. Ni-FIT a microcomputer program for non-linear fitting
7. A phase I study of a novel trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors
8. Predictive value of preclinical toxicology studies for platinum anticancer drugs